082800 — Vivozon Pharmaceutical Co Share Price
Last trade - 00:00- KR₩331bn
- KR₩360bn
- KR₩88bn
- 21
- 15
- 48
- 14
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.17 | ||
| Price to Tang. Book | 3.58 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.86 | ||
| EV to EBITDA | 68.33 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.6% | ||
| Return on Equity | -10.13% | ||
| Operating Margin | 2.05% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 43,591.51 | 57,729.54 | 51,564.31 | 71,317.79 | 87,601.35 | n/a | n/a | 14.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vivozon Pharmaceutical Co Ltd is a Korea-based company mainly engaged in the manufacture and sale of finished pharmaceutical products. The Company mainly engages in the business of ethical (ETC) drugs, over the counter (OTC) drugs, contract manufacture organization (CMO), original equipment manufacturer (OEM), and other overseas exports. The Company manufactures and sells ETC drugs such as circulatory system drugs, external skin preparations, antipyretics, analgesics, anti-inflammatory drugs, and antidiabetic drugs, as well as OTC drugs such as Lalaola, Inipoten, and Libertine, an adjuvant treatment for liver disease. In addition, the Company manufactures and supplies influenza drugs, digestive drugs, arteriosclerosis drugs, and central nervous system drugs. The Company also manufactures medical devices.
Directors
- Hyeon Seung Cho CCE (50)
- Jae Gwan Han CCE (54)
- Dae Sik Hong OTH (55)
- Hwan Sik Mok OTH (61)
- Su Bok Kim DRC (52)
- Yong Won Kim DRC (62)
- Myeong Gu Park DRC (66)
- Han Cheol Yoo NID (62)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 22nd, 2002
- Public Since
- November 18th, 2005
- No. of Shareholders
- 27,180
- No. of Employees
- 42
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 49,379,445
- Address
- 34-40, Jeyakgongdan 2-gil, Hyangnam-eup, YONGIN, 18622
- Web
- https://www.vivozonpharm.com/
- Phone
- +82 234347600
- Auditors
- Samil Accounting Corp.
Upcoming Events for 082800
Similar to 082800
AbClon
Korea Exchange - KOSDAQ
ADBiotech Co
Korea Exchange - KOSDAQ
AHN-GOOK PHARMACEUTICAL Co
Korea Exchange - KOSDAQ
Alteogen
Korea Exchange - KOSDAQ
Aminologics Co
Korea Exchange - KOSDAQ
FAQ
As of Today at 24:01 UTC, shares in Vivozon Pharmaceutical Co are trading at KR₩6,840. This share price information is delayed by 15 minutes.
Shares in Vivozon Pharmaceutical Co last closed at KR₩6,840 and the price had moved by +136.87% over the past 365 days. In terms of relative price strength the Vivozon Pharmaceutical Co share price has outperformed the FTSE Developed Asia Pacific Index by +139.58% over the past year.
There is no consensus recommendation for this security.
Find out moreVivozon Pharmaceutical Co does not currently pay a dividend.
Vivozon Pharmaceutical Co does not currently pay a dividend.
Vivozon Pharmaceutical Co does not currently pay a dividend.
To buy shares in Vivozon Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩6,840, shares in Vivozon Pharmaceutical Co had a market capitalisation of KR₩331bn.
Here are the trading details for Vivozon Pharmaceutical Co:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 082800
Based on an overall assessment of its quality, value and momentum Vivozon Pharmaceutical Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vivozon Pharmaceutical Co. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +47.27%.
As of the last closing price of KR₩6,840, shares in Vivozon Pharmaceutical Co were trading +16.68% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Vivozon Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩6,840.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Vivozon Pharmaceutical Co's management team is headed by:
- Hyeon Seung Cho - CCE
- Jae Gwan Han - CCE
- Dae Sik Hong - OTH
- Hwan Sik Mok - OTH
- Su Bok Kim - DRC
- Yong Won Kim - DRC
- Myeong Gu Park - DRC
- Han Cheol Yoo - NID